ANDA 87759, held by Baxter Healthcare. Prochlorperazine Edisylate.
As of Nov 21, 2026, ANDA 87759 (Prochlorperazine), held by Baxter Healthcare, was first approved by FDA on Oct 1, 1982, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 1, 1982 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| ProchlorperazineEQ 5MG BASE/ML · injectable;injection | Prochlorperazine Edisylate | Discontinued |
| May 1, 1992 | Supplement 10Manufacturing | Approved | None posted |
| Mar 4, 1992 | Supplement 11Manufacturing | Approved | None posted |
| Jan 16, 1991 | Supplement 12Labeling | Approved | None posted |
| Sep 15, 1989 | Supplement 9Labeling | Approved | None posted |
| Jan 31, 1989 | Supplement 8Labeling | Approved | None posted |
| Nov 3, 1986 | Supplement 6Manufacturing | Approved | None posted |
| Mar 23, 1984 | Supplement 3Manufacturing | Approved | None posted |
| Mar 1, 1984 | Supplement 2Manufacturing | Approved | None posted |
| Mar 9, 1983 | Supplement 1Manufacturing | Approved | None posted |
| Oct 1, 1982 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters